What began as a scientific pursuit has evolved into a robust technology platform grounded on archaeal tetraether lipids produced through our proprietary, patented processes.
Austria’s Biotech Future in Focus: NovoArc Hosts Federal Leaders
NovoArc GmbH had the honor of welcoming Federal Minister Dr. Wolfgang Hattmannsdorfer, Bundesvorsitzende der Jungen Wirtschaft Bettina Dorfer-Pauschenwein, and delegations from the Federal Ministry for Economic Affairs and Energy and the Austrian Federal Economic Chamber to NovoArc GmbH.
We are excited to announce the start of our Lipidosa Project in collaboration with Joanneum Graz, running from July 2025 to June 2027, focused on the pharmacological characterization of tetraetherlipid formulations for oral administration.
We are proud to announce our participation in the D2R Project Spotlight, a collaborative effort with leading researchers from McGill University, Dalhousie University, the University of Calgary, and RNA Technologies and Therapeutics.
We are proud to share that our Co-founder and CPO, Oliver Spadiut, delivered an inspiring talk during the Innovation Session at the Advanced Therapies Conference 2025 in London.
NovoArc GmbH has won the Phönix Start-up Award! Receiving this prestigious prize at the Haus der Industrie Industriellenvereinigung was an unforgettable moment in an amazing atmosphere – a recognition of the hard work we’ve put in over the past years.
We use cookies on our website. They help us to improve this website and the user experience (tracking cookies). You can decide for yourself whether you want to allow them.
